SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-23-000043
Filing Date
2023-11-02
Accepted
2023-11-02 06:01:35
Documents
14
Period of Report
2023-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20231102.htm   iXBRL 8-K 29556
2 EX-99.1 exhibit991_q32023pressrele.htm EX-99.1 134091
6 GRAPHIC aurinalogoa.jpg GRAPHIC 11010
  Complete submission text file 0001600620-23-000043.txt   314937

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20231102.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20231102_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20231102_pre.xml EX-101.PRE 12532
8 EXTRACTED XBRL INSTANCE DOCUMENT auph-20231102_htm.xml XML 2720
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 231369802
SIC: 2834 Pharmaceutical Preparations